TABLE 2.
Summary of results for clarithromycin pharmacokinetic parameters
| Parameter | GLSM (arithmetic mean, CV)a for:
|
Treatment 3 GLSM/treatment 2 GLSM ratio (90% CI) | |
|---|---|---|---|
| Treatment 2b | Treatment 3c | ||
| AUCss (h · μg/ml) | 21.40 (22.31, 29%) | 20.51 (20.92 21%) | 0.96 (0.83–1.11) |
| Cmax,ss (μg/ml) | 2.57 (2.70, 29%) | 2.31 (2.36, 19%) | 0.90 (0.76–1.07) |
| Cmin,ss (μg/ml) | 1.03 (1.06, 33%) | 1.04 (1.09, 28%) | 1.02 (0.87–1.20) |
| CL/F (ml/min) | 390 (405, 30%) | 406 (417, 25%) | 1.04 (0.90–1.21) |
| Tmax,ss (h)d | 2.25 (2.46, 73%) | 4.99 (4.79, 29%) | 2.00 (0.75–3.38) |
| CLR (ml/min) | 114 (121, 32%) | 154 (159, 21%) | 1.34 (1.17–1.54) |
| % Dosee | 31.25 (31.62, 35%) | 38.82 (38.63, 19%) | 1.24 (1.03–1.45) |
a
GLSM, geometric least-squares mean; CV, coefficient of variation.
b
Consists of 500 mg of clarithromycin twice a day.
c
Consists of 1,200 mg of amprenavir twice a day plus 500 mg of clarithromycin twice a day.
d
Median and median difference.
e
Least-squares mean and least-squares mean ratio.